Cover Image

LIQUID: treatment of high-grade dural arteriovenous fistulas with Squid liquid embolic agent$da prospective, observational multicenter study

Background Endovascular embolization is a feasible treatment for cranial dural arteriovenous fistulas (DAVFs). New embolic agents aim to improve the success of DAVF embolization. - Objective To assess the safety, efficacy, and short-term outcome of the treatment of DAVFs using the new liquid embolic...

Full description

Saved in:
Bibliographic Details
Main Authors: Vollherbst, Dominik (Author) , Boppel, Tobias (Author) , Wallocha, Marta (Author) , Berlis, Ansgar (Author) , Maurer, Christoph J. (Author) , Weber, Werner (Author) , Fischer, Sebastian (Author) , Bock, Alexander (Author) , Meckel, Stephan (Author) , Bohner, Georg (Author) , Liebig, Thomas (Author) , Herweh, Christian (Author) , Bendszus, Martin (Author) , Chapot, René (Author) , Möhlenbruch, Markus Alfred (Author)
Format: Article (Journal)
Language:English
Published: 2023
In: Journal of neuroInterventional surgery
Year: 2023, Volume: 15, Issue: 11, Pages: 1111-1116
ISSN:1759-8486
DOI:10.1136/jnis-2022-019859
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1136/jnis-2022-019859
Verlag, kostenfrei, Volltext: https://jnis.bmj.com/content/early/2023/01/23/jnis-2022-019859
Get full text
Author Notes:Dominik F. Vollherbst, Tobias Boppel, Marta Wallocha, Ansgar Berlis, Christoph J. Maurer, Werner Weber, Sebastian Fischer, Alexander Bock, Stephan Meckel, Georg Bohner, Thomas Liebig, Christian Herweh, Martin Bendszus, René Chapot, Markus A. Möhlenbruch
Description
Summary:Background Endovascular embolization is a feasible treatment for cranial dural arteriovenous fistulas (DAVFs). New embolic agents aim to improve the success of DAVF embolization. - Objective To assess the safety, efficacy, and short-term outcome of the treatment of DAVFs using the new liquid embolic agent Squid. - Methods The LIQUID study is a prospective, observational multicenter study on the treatment of high-grade (Cognard type ≥3) DAVFs with the embolic agent Squid. The primary outcome measures were safety (ie, morbidity and mortality), as well as the occlusion rate 90 to 180 days after treatment. - Results In eight centers, 53 patients (mean age 59.8 years, 22.6% female) were treated in 55 treatment sessions. Of the DAVFs, 56.6% were Cognard type III, 41.5% type IV, and 18.9% were ruptured. Squid 18 was used in 83.6% and Squid 12 in 32.7% of the treatments. The overall rate of intraprocedural or postprocedural adverse events (AEs) was 18.2%. Procedure-related AEs resulting in permanent morbidity were observed in 3.6%. One patient (1.8%) died unrelated to the procedure due to pulmonary embolism. The final complete occlusion rate at 90 to 180 days was 93.2%. After a mean follow-up of 5.5 months, the modified Rankin Scale (mRS) score was stable or improved in 93.0%. In one of the patients, worsening of the mRS score was related to the procedure (1.8%). - Conclusion Squid is a safe and effective liquid embolic agent for the treatment of high-grade DAVFs.
Item Description:First published January 6, 2023
Gesehen am 12.06.2023
Physical Description:Online Resource
ISSN:1759-8486
DOI:10.1136/jnis-2022-019859

Similar Items